Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in India

NCT05855967 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05855967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05855967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in India
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
June 27, 2023
Completion date
September 23, 2024
Enrollment
250 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriatic arthritis